Krsnaa Diagnostics Ltd

Krsnaa Diagnostics Ltd has announced the closure of its trading window from July 01, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. All directors, key managerial personnel, designated employees, promoters, and their immediate relatives are restricted from trading in the company's securities during this period to prevent potential insider trading. The date for the board meeting to approve these results will be communicated separately.

Krsnaa Diagnostics Ltd's board approved audited financial results for FY26 with an unmodified opinion from auditors. A final dividend of ₹2 per share (40% of face value) was recommended, subject to shareholder approval. The board also approved the appointment of M/s Kirtane & Pandit LLP as Statutory Auditors for FY27-31, and re-appointed internal, cost, and tax auditors for FY26-27.

Krsnaa Diagnostics Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. They recommended a final dividend of ₹2 per equity share (40% of face value) for FY26, subject to shareholder approval. The board also approved the appointment and re-appointment of various auditors, including the statutory auditors for FY27-31.

Krsnaa Diagnostics Ltd's board recommended a final dividend of ₹2 per equity share (40% of face value) for FY 2025-26, subject to shareholder approval at the AGM. The board also approved the audited standalone and consolidated financial results for the year ended March 31, 2026. Additionally, the board approved the appointment/re-appointment of various auditors, including the statutory auditors for FY 2026-27 to 2030-31.

Krsnaa Diagnostics Ltd's board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. They recommended a final dividend of ₹2 per equity share (40% of face value) for FY26, subject to shareholder approval. The board also approved the appointment and re-appointment of various auditors, including M/s Kirtane & Pandit LLP as Statutory Auditors for FY27-31, subject to shareholder approval. The meeting commenced at 13:30 Hrs (IST) and concluded at 18:00 Hrs (IST).

Krsnaa Diagnostics Ltd. has received assessment orders and demand notices from the Income Tax Department, Pune, for assessment years 2018-19 and 2019-20, resulting in a total income tax demand of ₹11,30,54,699. The company is challenging these orders and is confident of defending them. The disclosure was made following an internal compliance review. The identified contingent liability will require evaluation under Ind AS 37, but is not expected to cause operational disruption.

Krsnaa Diagnostics' Board of Directors, at its meeting on April 17, 2026, approved significant leadership and governance changes. Mr. Raju Venkatraman and Ms. Lilian Jessie Paul were appointed as Additional Independent Directors for two years, effective April 25, 2026. Mr. Chetan Desai was re-appointed as an Independent Director for a subsequent five-year term. Mr. Chandra Prakash Singh was appointed as Interim Chief Financial Officer from April 17, 2026. Ms. Pallavi Bhatevara ceased to be a Whole-time Director, and Mr. Rajiva Ranjan Verma and Ms. Chhaya Palrecha ceased to be Independent Directors, all due to tenure completion. The Board also reconstituted its Audit, Nomination & Remuneration, Corporate Social Responsibility, Stakeholders Relationship, and Risk Management Committees, effective April 25, 2026, reflecting the new board composition.

Krsnaa Diagnostics' Board of Directors, at its meeting on April 17, 2026, approved significant changes to its leadership and governance framework. Mr. Raju Venkatraman and Ms. Lilian Jessie Paul were appointed as Additional Independent Directors for two years, and Mr. Chetan Desai was re-appointed as an Independent Director for five years. Mr. Chandra Prakash Singh was appointed as Interim CFO. Concurrently, Ms. Pallavi Bhatevara ceased to be a Whole-time Director, and Mr. Rajiva Ranjan Verma and Ms. Chhaya Palrecha completed their tenures as Independent Directors. The Board also approved the reconstitution of key committees, including Audit, Nomination and Remuneration, Corporate Social Responsibility, Stakeholders Relationship, and Risk Management Committees, effective April 25, 2026. These changes aim to strengthen the company's board and committee leadership.

Krsnaa Diagnostics' Board of Directors, at its meeting on April 17, 2026, approved significant changes to its leadership and governance framework. Mr. Raju Venkatraman and Ms. Lilian Jessie Paul were appointed as Additional Independent Directors for two years. Mr. Chetan Desai was re-appointed as an Independent Director for five years. Mr. Chandra Prakash Singh was appointed as Interim CFO. Ms. Pallavi Bhatevara ceased to be a Whole-time Director, and Mr. Rajiva Ranjan Verma and Ms. Chhaya Palrecha ceased to be Independent Directors upon completion of their tenures. The Board also reconstituted its Audit, Nomination & Remuneration, CSR, Stakeholders Relationship, and Risk Management Committees, effective April 25, 2026. These changes aim to enhance the Board's experience and leadership.

Krsnaa Diagnostics Ltd has announced the resignation of Mr. Vivek Jain, the Head-Investor Relations of the Company. Mr. Jain has tendered his resignation due to personal reasons, with his last working day being March 31, 2026. The management has expressed gratitude for his services and contributions during his tenure. The required details as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, are enclosed as Annexure.